Skip to main content
Premium Trial:

Request an Annual Quote

Polyplus-transfection Lands $1.8M Financing

NEW YORK (GenomeWeb News) – Polyplus-transfection has raised €1.2 million ($1.8 million) through a new funding round from existing investors.

The Strasbourg, France-based firm said it plans to use the funding primarily for its RNAplus research program, which aims to generate new oligonucleotides that are capable of silencing the expression of a target gene through RNA interference without the need for a delivery reagent.

The investment came from the issue of convertible bonds and it was led by existing investor CIC-Vizille Capital Innovation, and the participation of Avenir Finance Gestion and CIC Finance-CIC Investissement Alsace.

Polyplus-transfection also plans to add a new CEO and business development manager for its operations in the US, which contributes 40 percent of the firm's sales.

It also expects that the financing will enable it to continue development of Zip Nucleic Acid oligonucleotides and to defend some of its intellectual property.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.